Evaluation of safety and efficacy of erlotinib as monotherapy for Chinese patients with advanced non-small cell lung cancer

被引：0
|
作者：
Zhang, Xiao-Tong [1 ]
Li, Long-Yun [1 ]
Wang, Meng-Zhao [1 ]
Zhang, Li [1 ]
Zhong, Wei [1 ]
Wang, Shu-Lan [1 ]
机构：
[1] Beijing Union Med Coll Hosp, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：184 / 185
页数：2
相关论文
共 50 条
  • [31] EFFICACY OF ERLOTINIB AFTER THE FAILURE OF GEFITINIB IN PATIENTS WITH ADVANCED OR METASTASIS NON-SMALL CELL LUNG CANCER
    Wang Yan
    Li Junling
    Wang Ziping
    Guo Jihong
    Yu Shufei
    Hao Xuezhi
    Hu Xingsheng
    Wang Bin
    Zhang Xiangru
    Shi Yuankai
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1238 - S1239
  • [32] Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials
    Gao, Hui
    Ding, Xin
    Wei, Dong
    Cheng, Peng
    Su, Xiaomei
    Liu, Huanyi
    Aziz, Fahad
    Wang, Daoyuan
    Zhang, Tao
    ANTI-CANCER DRUGS, 2011, 22 (09) : 842 - 852
  • [33] Erlotinib (Tarceva) for advanced non-small cell lung cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2005, 47 (1205): : 25 - 26
  • [34] Safety and efficacy of bevacizumab in "fragile" patients with advanced non-small cell lung cancer
    Maragkos, C.
    Grapsa, D.
    Koumakis, G.
    Polyzos, A.
    Syrigos, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [35] Reviewing the safety of erlotinib in non-small cell lung cancer
    Reck, Martin
    Mok, Tony
    Wolf, Juergen
    Heigener, David
    Wu, Yi-long
    EXPERT OPINION ON DRUG SAFETY, 2011, 10 (01) : 147 - 157
  • [36] Efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with non-small cell lung cancer
    Chikaishi, Yasuhiro
    Inoue, Masaaki
    Kusanagi, Kasumi
    Honda, Yohei
    Yoshida, Junichi
    Tanaka, Masao
    AGING MEDICINE, 2021, 4 (01) : 42 - 46
  • [37] Clinical pharmacokinetics, safety, and preliminary efficacy evaluation of icotinib in patients with advanced non-small cell lung cancer
    Liu, Dongyang
    Zhang, Li
    Wu, Yiwen
    Jiang, Ji
    Tan, Fenlai
    Wang, Yingxiang
    Liu, Yong
    Hu, Pei
    LUNG CANCER, 2015, 89 (03) : 262 - 267
  • [38] IMPACT AND SAFETY PROFILE OF ERLOTINIB TREATMENT IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER - A SMALL PROSPECTIVE STUDY
    Mazilu, Laura
    Iorga, Polixenia
    Suceveanu, Andra-Iulia
    Parepa, Irinel
    Suceveanu, Adrian
    Tofolean, Doina
    Adam, Tatiana
    Jinga, Dan
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1234 - S1234
  • [39] Evaluation of efficacy and safety of ZD1839 as monotherapy for Chinese patients with advanced non-small cell lung cancer: Experience from a compassionate-use programme.
    Wang, MZ
    Li, LY
    Wang, SL
    Zhang, XT
    Zhong, W
    Zhang, L
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 683S - 683S
  • [40] Efficacy and Safety of Combing Anlotinib and Erlotinib as a First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Han, B.
    Chu, T.
    Shi, C.
    Zhong, H.
    Zhang, W.
    Zhang, B.
    Zhong, R.
    Zhang, X.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S646 - S647
12345